<DOC>
	<DOCNO>NCT00002562</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness paclitaxel treat patient advance , refractory , recurrent cervical vaginal cancer .</brief_summary>
	<brief_title>Paclitaxel Treating Patients With Advanced , Refractory , Recurrent Cervical Vaginal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate frequency duration objective response , duration progression-free interval , survival patient treat paclitaxel advance , persistent , recurrent clear cell adenocarcinoma vagina cervix fail high priority treatment protocol . II . Determine frequency severity observe adverse effect study . OUTLINE : Single-Agent Chemotherapy . Paclitaxel , TAX , NSC-673089 . PROJECTED ACCRUAL : 25 evaluable patient per histologic stratum accrue 10-12 month nonsquamous cell carcinoma stratum 23 month clear cell adenocarcinoma stratum . If 3 patient give stratum respond , additional 25 patient accrue stratum . As 07/95 , study open patient clear cell adenocarcinoma vagina cervix .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced , persistent , recurrent clear cell adenocarcinoma vagina cervix Documented disease progression local therapy require Disease must consider incurable Bidimensionally measurable disease require physical examination medical imaging PATIENT CHARACTERISTICS : Age : Any age Performance status : GOG 02 Hematopoietic : WBC least 3,000 AGC least 1,500 Platelets least 100,000 Hepatic : Bilirubin 1.5 time normal AST 3 time normal Alkaline phosphatase 3 time normal Renal : Creatinine 2.0 mg/dL Other : Not eligible high priority GOG protocol No significant infection No prior concomitant second malignancy except nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : At least 3 week since therapy direct malignancy Biologic therapy : Not specify Chemotherapy : No 1 prior chemotherapy regimen ( either single combination cytotoxic drug therapy ) No prior paclitaxel Recovery prior chemotherapy required Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy recurrent disease except low dose , single fraction use abrogate menorrhagia Recovery prior radiotherapy require Surgery : Recovery prior surgery require</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>recurrent vaginal cancer</keyword>
	<keyword>vaginal clear cell adenocarcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
</DOC>